This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Empowering the IPF Patient through Shared Decision Making, Multidisciplinary Care, and Treatment Awareness

Empowering the IPF Patient through Shared Decision Making, Multidisciplinary Care, and Treatment Awareness



Time to Complete

1 hour


December 20, 2018


December 20, 2019
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditsTM

Accredited Provider

Provided by the Academy for Continued Healthcare Learning (ACHL).

Commercial Supporter

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Program Description

Dr. Gregory Cosgrove discusses recent guidelines for an IPF diagnosis, pharmacological and nonpharmacologic approaches to treat IPF, new and emerging science, and strategies to encourage shared decision making. Fred Haley, a patient ambassador, also provides the patient perspective throughout the activity.

Intended Audience

This CME activity is intended for pulmonologists, radiologists, pathologists, respiratory nurses, respiratory therapists, and other clinicians interested in treatment advances for patients with IPF.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Outline needs and concerns of IPF patients over the disease course
  • Discuss guideline recommendations for differentiating IPF from other interstitial lung diseases to ensure a definitive diagnosis
  • Interpret the efficacy and safety data for pharmacotherapies used to treat IPF
  • Formulate comprehensive management plans, including pharmacologic and nonpharmacologic approaches and support strategies
  • Engage patients and their families in shared decision making for the management of IPF
  • Describe the benefits and roles of multidisciplinary team over the course of IPF

Conflict Of Interest Disclosure Policy

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.


Gregory P. Cosgrove, MD, FCCP
Associate Professor
National Jewish Health &
University of Colorado-Denver
Chief Medical Officer,
Pulmonary Fibrosis Foundation
Denver, CO

Dr. Cosgrove discloses the following:
Grants/Research Support recipient: Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Global Blood Therapeutics
Advisor or Review Panel member: Boehringer Ingelheim, Genentech, Global Blood Therapeutics
Consultant (Occasional): Boehringer Ingelheim, Genentech, Global Blood Therapeutics

Fred Haley
PFF Support Group Leader & Patient Advocate
Pulmonary Fibrosis Foundation
Greensboro, NC

Mr. Haley has no relationships to disclose.

Accredited Provider Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Therapies under investigation for IPF


The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.


This activity will take approximately 1 hour to complete. To receive credit, participants are required to complete the pre-test, view the activity, and complete the post-test and evaluation. To receive credit, 60% must be achieved on the post-test. A certificate will be immediately available. There is no fee for the generation of the certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please call ACHL at (877) 444-8435, ext. 160.


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue